This trial is evaluating whether Sapanisertib will improve 5 primary outcomes and 12 secondary outcomes in patients with Advanced Malignant Solid Neoplasm. Measurement will happen over the course of Up to 42 days.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. Sapanisertib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Not yet. But the new CRISPR-Cas9 system does have potential to destroy cancer. I would like to see (and maybe, someday I hope, experience) it being used to treat multiple cancers - including leiomyosarcoma - in patients. So where’s Leyo?" - Anonymous Online Contributor
"About 3.7 million people a year are expected to develop cancer; 1.6 million from lung cancer, 1.3 million from prostate cancer, and 0.8 million from colon cancer. These numbers will increase as the overall US population ages." - Anonymous Online Contributor
"Cancer is an incurable disease that occurs when cells are no longer able to regulate themselves. There are more than 20 common cancer types and there are many rarer types. Most cancers are caused by environmental agents such as tobacco, excessive alcohol use, or chemicals such as the hepatitis B virus. The disease typically arises from normal body cells and the rate of tumour formation is lower in those with good immunity. Tumour cells invade surrounding tissues and set up camps so that they may grow new blood vessels and other nutrients. The exact cause of cancer remains unclear. The disease is not contagious." - Anonymous Online Contributor
"Common treatment for cancer includes radiation, biotherapy, surgery, chemotherapy, and hormonal therapy (HRT). The prognosis of cancer depends on the staging, where the best treatment options are determined by how advanced the cancer is, and treatment options for individuals vary vastly in a given population (or type of cancer). There is no cure or vaccine, and treatment typically involves surgery to remove or destroy cancer cells or tumors.\n" - Anonymous Online Contributor
"Cancer therapy can prevent cancer symptoms. However, given the present level of cancer control, it is probably impossible to eradicate cancer completely, which indicates that cancer can not be cured but only prevented." - Anonymous Online Contributor
"The key signs of cancer are nonspecific: the presence of a malignancy, suspicion of cancer, the effects of cancer. Malignancy can be recognised by one of several approaches including a thorough medical examination by a medical practitioner, the observation of the physical signs with the aid of the patient's history and family history, or by using a specific test such as a blood test or scan to detect tumour." - Anonymous Online Contributor
"The causes of cancer are varied and include genetic (single gene disorders), environmental (environmental carcinogens,) random (mistakes during cell division, or chemical and physical hazards) and infectious (viral, bacterial or parasitic infections) causation. Although cancer may be diagnosed and treated quickly, it still has a high percentage of non-treatable cases that do not respond to treatment. Because cancer affects people of all ages, both male and female, it is difficult to pinpoint when the disease starts, but cancer has no specific age of onset, at least, in people who are alive at the time of diagnosis. If cancer does have a definite age of onset, it does not always occur soon after the disease begins." - Anonymous Online Contributor
"Results from a recent paper suggest that the treatment with SAP has a positive impact on HRQoL and symptoms and this effect seems to be independent from the efficacy of the treatment, as shown by the good tolerability." - Anonymous Online Contributor
"Panobinostat and sapanisertib are inhibitors of both HDAC1 and HDAC2. Therefore, they exert the antiproliferative activity by interfering with the repression of transcriptional coregulator and histone modifications of the target genes. Findings from a recent study of this study indicate the potential of combining these drugs in the treatment of a broad spectrum of hematological malignancies such as myeloid leukemia, lymphoid leukemia, and Hodgkin lymphoma." - Anonymous Online Contributor
"Results from a recent paper population with a mean age of 67 years and almost 70 years in the first decade of life and the first 30 years of adulthood, nearly a quarter of patients had experienced one or more types of cancer, but one third of the patients who underwent surgery for cancer had died of the disease. While about half of the patients who underwent surgery with curative intent had been cured of the disease, this seemed to be by no means guaranteed. As expected, most fatal cancer could be traced back to smoking – a fact that would only be of significance if smoking were not an absolute impediment to the curative potential of surgery. This should alert us to the reality of cancer, and to the importance of primary prevention." - Anonymous Online Contributor
"The majority of patients, on clinical trial assessments, had a poor understanding of randomization and study design and the implications of that. Clinicians should make more effort to make patients more knowledgeable about their options when they are diagnosed with cancer and to help them navigate the options and the treatment options. Patients with cancer are particularly willing to participate in clinical trials, despite the increased risk related to enrollment, but clinicians should maximize their opportunities to educate patients. Understanding, understanding, and respecting patients with cancer and their unique beliefs and experiences about their illness, therapy, and options should always take precedence in clinical trials." - Anonymous Online Contributor
"The identification of patients responsive to a dose of 150 mg twice daily, the ability to use this dose in combination with capecitabine and a reduced exposure at this dose, together with the potential to use a dose-dependent combination regimen of sapanisertib in combination in patients with metastatic tumors, make sapanisertib a very attractive molecule in the treatment of cancer." - Anonymous Online Contributor